First Patient Dosed in Combination Cancer Therapy Trial
The BLAZE trial tests if bexmarilimab can re-sensitize patients with melanoma and lung cancer to immunotherapy.
Updated on Oct. 1, 2026 in Cancer
Live Poll
Should pharmaceutical companies prioritize smaller, academic-led clinical trials to broaden the use of their existing drugs?
Faron Pharmaceuticals has officially begun the BLAZE trial, an investigator-initiated study exploring a new combination therapy for advanced cancers. This Phase I/II trial enrolls patients with non-small cell lung cancer (NSCLC) and melanoma whose disease has progressed despite previous treatment.
Why it matters
This study addresses the challenge of acquired resistance to standard anti-PD-1 cancer therapies. By testing a potential re-sensitizer, researchers aim to determine if this combination can restore treatment efficacy for patients who have exhausted existing options.
The BLAZE trial is a Phase I/II study designed to evaluate the safety and clinical activity of bexmarilimab combined with nivolumab. The study focuses specifically on a population of patients with NSCLC and melanoma who have previously progressed on anti-PD-1 therapy.
The players
Faron Pharmaceuticals
A clinical-stage biopharmaceutical company focused on developing therapies for hematological and solid tumor cancers.
The details
Bexmarilimab is being investigated for its potential to act as a checkpoint inhibitor re-sensitizer in patients who no longer respond to conventional immunotherapy. The trial works by pairing this asset with nivolumab, a standard anti-PD-1 drug, to target immune evasion pathways. By inhibiting these specific pathways, the treatment seeks to reignite the immune system’s ability to recognize and attack tumor cells in patients whose cancer has developed resistance.
Timeline
October 1, 2026: The first patient was dosed in the BLAZE trial.
Health Landscape
The BLAZE trial marks a strategic effort to overcome treatment resistance in the era of anti-PD-1 checkpoint inhibitors. This study follows a broader trend in oncology research focused on extending the durability of immunotherapy by combining established agents with novel sensitizing drugs.
This early-stage research is currently limited to patients with specific cancer types who have already progressed on standard immunotherapy. If you or a loved one are facing treatment resistance, it is worth discussing the status of ongoing clinical trials with your oncologist.
The takeaway
The BLAZE trial represents a new effort to restore sensitivity to immunotherapy for patients with advanced melanoma or lung cancer. Patients should track the progress of clinical trials through their care team to understand when new combination approaches might become accessible.
Further reading
For more on the current methods used to target solid tumors, see our latest research in Cancer.
Live Poll
Should pharmaceutical companies prioritize smaller, academic-led clinical trials to broaden the use of their existing drugs?
